A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both (SURPASS-PEDS)
The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diabetes taking metformin, or basal insulin, or both.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participants must have type 2 diabetes treated with metformin and/or long-acting insulin
Participants must have glycated hemoglobin (HbA1c) greater than 6.5% to no more than 11% at screening visit
Participants must be overweight or obese
Participants Must Not:
Participants must not have type 1 diabetes mellitus (T1DM)
Participants must not have history of inflammation of the pancreas
Participants must not be pregnant or breastfeeding
Participants must not have had one or more events of very low blood sugar in the past 6 months
Participants must not be taking prescription or over the counter weight loss medication
Participants must not have a personal or family history of certain neck cancer
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo